Why should elderly AML patients take part in clinical trials?
Promising CLL & FL data from ICML 2017: BGB-3111 and obinituzumab
Understanding the complexity of acute myeloid leukemia (AML)
What does the CLL forum data tell us?
ASH highlights: groundbreaking results from the TEAMM trial